Neuroendocrine Tumors

"Neuroendocrine Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.

Descriptor ID	D018358
MeSH Number(s)	C04.557.465.625.650 C04.557.580.625.650
Concept/Terms	Neuroendocrine Tumors Neuroendocrine Tumors Neuroendocrine Tumor Tumor, Neuroendocrine Tumors, Neuroendocrine

Below are MeSH descriptors whose meaning is more general than "Neuroendocrine Tumors".

Diseases [C]
Neoplasms [C04]
Neoplasms by Histologic Type [C04.557]
Neoplasms, Germ Cell and Embryonal [C04.557.465]
Neuroectodermal Tumors [C04.557.465.625]
Neuroendocrine Tumors [C04.557.465.625.650]
Neoplasms, Nerve Tissue [C04.557.580]
Neuroectodermal Tumors [C04.557.580.625]
Neuroendocrine Tumors [C04.557.580.625.650]

Below are MeSH descriptors whose meaning is related to "Neuroendocrine Tumors".

Below are MeSH descriptors whose meaning is more specific than "Neuroendocrine Tumors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Neuroendocrine Tumors" by people in this website by year, and whether "Neuroendocrine Tumors" was a major or minor topic of these publications.

Bar chart showing 280 publications over 28 distinct years, with a maximum of 25 publications in 2014

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1994	1	0	1
1995	1	0	1
1996	2	0	2
1997	2	0	2
1998	3	2	5
1999	2	0	2
2000	0	1	1
2001	1	0	1
2003	1	0	1
2004	5	0	5
2005	2	2	4
2006	6	1	7
2007	8	0	8
2008	8	1	9
2009	4	1	5
2010	12	1	13
2011	20	1	21
2012	14	4	18
2013	10	1	11
2014	24	1	25
2015	16	1	17
2016	20	2	22
2017	20	0	20
2018	11	1	12
2019	18	0	18
2020	17	4	21
2021	23	1	24
2022	4	0	4

Below are the most recent publications written about "Neuroendocrine Tumors" by people in Profiles.

Dasari A, Shen C, Devabhaktuni A, Nighot R, Sorbye H. Survival According to Primary Tumor Location, Stage, and Treatment Patterns in Locoregional Gastroenteropancreatic High-grade Neuroendocrine Carcinomas. Oncologist. 2022 Apr 05; 27(4):299-306.

View in: PubMed
Erstad DJ, Dasari A, Taggart MW, Kaur H, Konishi T, Bednarski BK, Chang GJ. ASO Visual Abstract: Prognosis for Poorly Differentiated High-Grade Rectal Neuroendocrine Carcinomas. Ann Surg Oncol. 2022 04; 29(4):2549.

View in: PubMed
Morani AC, Gupta S, Elsayes KM, Mubarak AI, Khalaf AM, Bhosale PR, Sun J, Jensen CT, Kundra V. Performance of Multidetector Computed Tomography and Negative Versus Positive Enteric Contrast for Evaluation of Gastrointestinal Neuroendocrine Neoplasms. J Comput Assist Tomogr. 2022 May-Jun 01; 46(3):333-343.

View in: PubMed
Maxwell JE, Naraev B, Halperin DM, Choti MA, Halfdanarson TR. Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis. Ann Surg Oncol. 2022 May; 29(5):3072-3084.

View in: PubMed
Das S, Chauhan A, Du L, Thomas KE, Jacob A, Schad A, Jain S, Jessop A, Shah C, Eisner D, Cardin DB, Ciombor KK, Goff LW, Bradshaw M, Delbeke D, Sandler M, Ramirez RA, Berlin J. External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy. JAMA Netw Open. 2022 01 04; 5(1):e2144170.

View in: PubMed
Jonasch E, Donskov F, Iliopoulos O, Rathmell WK, Narayan VK, Maughan BL, Oudard S, Else T, Maranchie JK, Welsh SJ, Thamake S, Park EK, Perini RF, Linehan WM, Srinivasan R. Belzutifan for Renal Cell Carcinoma in von Hippel-Lindau Disease. N Engl J Med. 2021 11 25; 385(22):2036-2046.

View in: PubMed
Fahrmann JF, Wasylishen AR, Pieterman CRC, Irajizad E, Vykoukal J, Murage E, Wu R, Dennison JB, Krishna H, Peterson CB, Lozano G, Zhao H, Do KA, Halperin DM, Agarwal SK, Blau JE, Del Rivero J, Nilubol N, Walter MF, Welch JM, Weinstein LS, Vriens MR, van Leeuwaarde RS, van Treijen MJC, Valk GD, Perrier ND, Hanash SM. A Blood-based Polyamine Signature Associated With MEN1 Duodenopancreatic Neuroendocrine Tumor Progression. J Clin Endocrinol Metab. 2021 11 19; 106(12):e4969-e4980.

View in: PubMed
Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, Mittra E, Wolin EM, Yao JC, Pavel ME, Grande E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Mariani MF, Demange A, Mutevelic S, Krenning EP. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021 12; 22(12):1752-1763.

View in: PubMed
Sarvepalli S, Husain NS. Paraneoplastic Achalasia Associated With Neuroendocrine Tumor. Am J Gastroenterol. 2021 11 01; 116(11):2306.

View in: PubMed
Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O'Toole D, Sundin A, Prasad V. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. J Neuroendocrinol. 2022 03; 34(3):e13040.

View in: PubMed

People

Explore

Similar Concepts

Top Journals